{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:07:55Z","timestamp":1787933275962,"version":"build-2784847793"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0871900"],"award-info":[{"award-number":["2023YFC0871900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]},{"name":"Shanghai Science and Technology Support Program","award":["23S11902000"],"award-info":[{"award-number":["23S11902000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mpox (monkeypox) infection cases increased recently in non-Mpox outbreak areas, potentially causing an international threat. The desire to defend against a potential outbreak has led to renewed efforts to develop Mpox vaccines. In this report, mice were immunized with various doses of modified vaccinia virus Ankara (MVA) to evaluate the cross-reactive immune response of MVA immunization against protective antigens of the current monkeypox virus. We demonstrated that MVA induced specific antibodies against protective antigens (A29, A35, B6, M1, H3, and I1), mediating the neutralization abilities against the MVA and the monkeypox virus (MPXV). Moreover, recombinant protective antigens of the MPXV elicited cross-binding and cross-neutralizing activities for MVA. Hence, the MVA induced cross-reactive immune responses, which may guide future efforts to develop vaccines against the recent MPXV. Notably, compared to the other protective antigens, the predominant A29 and M1 antigens mediated higher cross-neutralizing immune responses against the MVA, which could serve as antigen targets for novel orthologous orthopoxvirus vaccine.<\/jats:p>","DOI":"10.1186\/s12985-023-02085-0","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T05:02:14Z","timestamp":1687150934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cross-reactive immune responses to monkeypox virus induced by MVA vaccination in mice"],"prefix":"10.1186","volume":"20","author":[{"given":"Feixia","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjingwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"issue":"2","key":"2085_CR1","doi-asserted-by":"publisher","first-page":"e0010141","DOI":"10.1371\/journal.pntd.0010141","volume":"16","author":"EM Bunge","year":"2022","unstructured":"Bunge EM, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141.","journal-title":"PLoS Negl Trop Dis"},{"key":"2085_CR2","doi-asserted-by":"crossref","unstructured":"Shchelkunov SN. Orthopoxvirus Genes That Mediate Disease Virulence and Host Tropism. Advances in Virology, 2012. 2012: p.\u00a01\u201317.","DOI":"10.1155\/2012\/524743"},{"issue":"7","key":"2085_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nm1261","volume":"11","author":"Y Edghill-Smith","year":"2005","unstructured":"Edghill-Smith Y, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med. 2005;11(7):740\u20137.","journal-title":"Nat Med"},{"issue":"14","key":"2085_CR4","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.3390\/ijms23147866","volume":"23","author":"D Kmiec","year":"2022","unstructured":"Kmiec D. Monkeypox:a New Threat?. Int J Mol Sci. 2022;23(14):7866.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2085_CR5","doi-asserted-by":"publisher","first-page":"e0150421","DOI":"10.1128\/JVI.01504-21","volume":"96","author":"EM Mucker","year":"2022","unstructured":"Mucker EM, et al. A nucleic acid-based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 proteins protects rabbits against Lethal Rabbitpox Virus Aerosol Challenge. J Virol. 2022;96(3):e0150421.","journal-title":"J Virol"},{"issue":"1","key":"2085_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/14760584.8.1.13","volume":"8","author":"JS Kennedy","year":"2009","unstructured":"Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines. 2009;8(1):13\u201324.","journal-title":"Expert Rev Vaccines"},{"issue":"14","key":"2085_CR7","doi-asserted-by":"publisher","first-page":"7805","DOI":"10.1128\/JVI.03481-12","volume":"87","author":"GJ Hatch","year":"2013","unstructured":"Hatch GJ, et al. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol. 2013;87(14):7805\u201315.","journal-title":"J Virol"},{"issue":"40","key":"2085_CR8","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1016\/j.vaccine.2009.06.105","volume":"27","author":"NL Garza","year":"2009","unstructured":"Garza NL, et al. Evaluation of the efficacy of modified vaccinia Ankara (MVA)\/IMVAMUNE\u00ae against aerosolized rabbitpox virus in a rabbit model. Vaccine. 2009;27(40):5496\u2013504.","journal-title":"Vaccine"},{"issue":"23","key":"2085_CR9","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","volume":"32","author":"SE Frey","year":"2014","unstructured":"Frey SE, et al. Phase II randomized, double-blinded comparison of a single high dose (5\u00d710(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1\u00d710(8) TCID50) in healthy vaccinia-nave individuals. Vaccine. 2014;32(23):2732\u20139.","journal-title":"Vaccine"},{"issue":"11","key":"2085_CR10","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1016\/j.vaccine.2020.01.058","volume":"38","author":"A Eto","year":"2020","unstructured":"Eto A, et al. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS - ScienceDirect. Vaccine. 2020;38(11):2600\u20137.","journal-title":"Vaccine"},{"key":"2085_CR11","doi-asserted-by":"crossref","unstructured":"Tiecco G et al. Monkeypox, a literature review: what is New and where does this concerning Virus come from? Viruses, 2022. 14(9).","DOI":"10.3390\/v14091894"},{"issue":"8","key":"2085_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/vaccines10081342","volume":"10","author":"KC See","year":"2022","unstructured":"See KC. Vaccination for Monkeypox Virus infection in humans: a review of key considerations. Vaccines. 2022;10(8):1342.","journal-title":"Vaccines"},{"issue":"10","key":"2085_CR13","first-page":"2220","volume":"28","author":"J Isidro","year":"2022","unstructured":"Isidro J. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Erratum in: Nat Med. 2022;28(10):2220\u20131.","journal-title":"Erratum in: Nat Med"},{"issue":"19","key":"2085_CR14","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","volume":"78","author":"C Fogg","year":"2004","unstructured":"Fogg C, et al. Protective immunity to Vaccinia Virus Induced by Vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol. 2004;78(19):10230.","journal-title":"J Virol"},{"issue":"7","key":"2085_CR15","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1128\/jvi.66.7.4170-4179.1992","volume":"66","author":"R Blasco","year":"1992","unstructured":"Blasco R, Moss B. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol. 1992;66(7):4170\u20139.","journal-title":"J Virol"},{"key":"2085_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/978-1-4615-5331-1_51","volume":"440","author":"GL Smith","year":"1998","unstructured":"Smith GL, Vanderplasschen A. Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Adv Experimental Med Biology. 1998;440:395.","journal-title":"Adv Experimental Med Biology"},{"issue":"16","key":"2085_CR17","doi-asserted-by":"publisher","first-page":"e0085221","DOI":"10.1128\/JVI.00852-21","volume":"95","author":"AM Schin","year":"2021","unstructured":"Schin AM, Diesterbeck US, Moss B. Insights into the Organization of the Poxvirus Multicomponent Entry-Fusion Complex from Proximity analyses in living infected cells. J Virol. 2021;95(16):e0085221.","journal-title":"J Virol"},{"issue":"7","key":"2085_CR18","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1128\/JVI.01854-07","volume":"82","author":"A Berhanu","year":"2008","unstructured":"Berhanu A, et al. Vaccination of BALB\/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol. 2008;82(7):3517\u201329.","journal-title":"J Virol"},{"key":"2085_CR19","doi-asserted-by":"crossref","unstructured":"Singh K et al. The Vaccinia Virus H3 envelope protein, a major target of neutralizing antibodies, exhibits a glycosyltransferase fold and binds UDP-Glucose. J Virol, 2016: p. 5020.","DOI":"10.2210\/pdb5ej0\/pdb"},{"issue":"1","key":"2085_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","volume":"239","author":"Bernard and Moss","year":"2010","unstructured":"Bernard and Moss. Smallpox vaccines: targets of protective immunity. Immunol Rev. 2010;239(1):8\u201326.","journal-title":"Immunol Rev"},{"issue":"2","key":"2085_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1006\/viro.1993.1302","volume":"194","author":"M Engelstad","year":"1993","unstructured":"Engelstad M, Smith GL. The Vaccinia Virus 42-kDa envelope protein is required for the Envelopment and Egress of Extracellular Virus and for Virus Virulence. Virology. 1993;194(2):627\u201337.","journal-title":"Virology"},{"issue":"Pt 6","key":"2085_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1099\/0022-1317-79-6-1415","volume":"79","author":"CM Sanderson","year":"1998","unstructured":"Sanderson CM, et al. Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion. J Gen Virol. 1998;79(Pt 6):1415\u201325.","journal-title":"J Gen Virol"},{"issue":"1","key":"2085_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.virol.2004.07.024","volume":"328","author":"Shlomo","year":"2004","unstructured":"Shlomo, et al. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement - ScienceDirect. Virology. 2004;328(1):30\u20135.","journal-title":"Virology"},{"issue":"3","key":"2085_CR24","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","volume":"167","author":"I Gilchuk","year":"2016","unstructured":"Gilchuk I, et al. Cross-neutralizing and protective human antibody specificities to Poxvirus Infections. Cell. 2016;167(3):684\u2013694e9.","journal-title":"Cell"},{"key":"2085_CR25","first-page":"59","volume-title":"Easy and efficient protocols for working with recombinant Vaccinia Virus MVA","author":"M Kremer","year":"2012","unstructured":"Kremer M, et al. Easy and efficient protocols for working with recombinant Vaccinia Virus MVA. Totowa, NJ: Humana Press; 2012. pp. 59\u201392."},{"key":"2085_CR26","doi-asserted-by":"crossref","unstructured":"Cotter CA. E.P.W.L., Preparation of Cell Cultures and vaccinia virus stocks. Curr Protoc Mol Biol, 2017. 5(117): p.\u00a016.16.1-16.16.18.","DOI":"10.1002\/cpmb.33"},{"issue":"3","key":"2085_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/pathogens11030320","volume":"11","author":"CH Rhee","year":"2022","unstructured":"Rhee CH, Her M, Jeong W. Modified Vaccinia Virus Ankara as a potential Biosafety Level 2 Surrogate for African Swine Fever Virus in Disinfectant Efficacy tests. Pathogens. 2022;11(3):320.","journal-title":"Pathogens"},{"issue":"1","key":"2085_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","volume":"306","author":"JW Hooper","year":"2003","unstructured":"Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology. 2003;306(1):181\u201395.","journal-title":"Virology"},{"issue":"7","key":"2085_CR29","doi-asserted-by":"publisher","first-page":"e42353","DOI":"10.1371\/journal.pone.0042353","volume":"7","author":"JW Golden","year":"2012","unstructured":"Golden JW, et al. Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates. PLoS ONE. 2012;7(7):e42353\u20133.","journal-title":"PLoS ONE"},{"issue":"6979","key":"2085_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature02331","volume":"428","author":"PL Earl","year":"2004","unstructured":"Earl PL, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004;428(6979):182\u20135.","journal-title":"Nature"},{"key":"2085_CR31","doi-asserted-by":"publisher","first-page":"102402","DOI":"10.1016\/j.tmaid.2022.102402","volume":"49","author":"N Luna","year":"2022","unstructured":"Luna N, et al. Phylogenomic analysis of the monkeypox virus (MPXV) 2022 outbreak: emergence of a novel viral lineage? Travel Med Infect Dis. 2022;49:102402.","journal-title":"Travel Med Infect Dis"},{"key":"2085_CR32","doi-asserted-by":"publisher","DOI":"10.1101\/2022.06.28.497936","volume-title":"Genomic regions insertion and deletion in Monkeypox virus causing multi-country outbreak-2022","author":"PA Desingu","year":"2022","unstructured":"Desingu PA, Nagarajan K. Genomic regions insertion and deletion in Monkeypox virus causing multi-country outbreak-2022. Cold Spring Harbor Laboratory Press: Cold Spring Harbor; 2022."},{"issue":"1","key":"2085_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0014-5793(01)03144-1","volume":"509","author":"SN Shchelkunov","year":"2001","unstructured":"Shchelkunov SN, et al. Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett. 2001;509(1):66\u201370.","journal-title":"FEBS Lett"},{"issue":"2","key":"2085_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1006\/viro.1998.9123","volume":"244","author":"G Antoine","year":"1998","unstructured":"Antoine G, et al. The complete genomic sequence of the modified Vaccinia Ankara strain: comparison with other Orthopoxviruses. Virology. 1998;244(2):365\u201396.","journal-title":"Virology"},{"key":"2085_CR35","doi-asserted-by":"crossref","unstructured":"Yang L et al. Immunization of mice with vaccinia virus Tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus. Virol Sin, 2022.","DOI":"10.1016\/j.virs.2022.10.004"},{"issue":"10","key":"2085_CR36","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/vaccines10101683","volume":"10","author":"F Gao","year":"2022","unstructured":"Gao F, et al. AddaVax-Adjuvanted H5N8 inactivated Vaccine induces robust Humoral Immune response against different clades of H5 viruses. Vaccines. 2022;10(10):1683.","journal-title":"Vaccines"},{"issue":"1","key":"2085_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","volume":"341","author":"S Coulibaly","year":"2005","unstructured":"Coulibaly S, et al. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology. 2005;341(1):91\u2013101.","journal-title":"Virology"},{"issue":"18","key":"2085_CR38","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.1128\/JVI.00945-14","volume":"88","author":"A Volz","year":"2014","unstructured":"Volz A, et al. Rapid expansion of CD8 + T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara. J Virol. 2014;88(18):10946\u201357.","journal-title":"J Virol"},{"issue":"1","key":"2085_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1073\/pnas.262668999","volume":"100","author":"I Drexler","year":"2003","unstructured":"Drexler I, et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A. 2003;100(1):217\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2085_CR40","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","volume":"28","author":"JD Miller","year":"2008","unstructured":"Miller JD, et al. Human effector and memory CD8 + T cell responses to Smallpox and Yellow Fever Vaccines. Immunity. 2008;28(5):710\u201322.","journal-title":"Immunity"},{"issue":"32","key":"2085_CR41","doi-asserted-by":"publisher","first-page":"14292","DOI":"10.1073\/pnas.1009234107","volume":"107","author":"M Mitsdoerffer","year":"2010","unstructured":"Mitsdoerffer M, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A. 2010;107(32):14292\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2085_CR42","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1128\/IAI.01392-09","volume":"78","author":"TM Wozniak","year":"2010","unstructured":"Wozniak TM, et al. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun. 2010;78(10):4187\u201394.","journal-title":"Infect Immun"},{"issue":"12","key":"2085_CR43","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.vaccine.2021.01.071","volume":"39","author":"M Khanna","year":"2021","unstructured":"Khanna M, et al. Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates. Vaccine. 2021;39(12):1780\u20137.","journal-title":"Vaccine"},{"issue":"1","key":"2085_CR44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","volume":"29","author":"MM Lamers","year":"2023","unstructured":"Lamers MM, et al. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med. 2023;29(1):270\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"2085_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1006\/viro.1998.9516","volume":"254","author":"MC Galmiche","year":"1999","unstructured":"Galmiche MC, et al. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology. 1999;254(1):71\u201380.","journal-title":"Virology"},{"issue":"9","key":"2085_CR46","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1128\/JVI.02878-15","volume":"90","author":"T Kaever","year":"2016","unstructured":"Kaever T, et al. Linear Epitopes in Vaccinia Virus A27 are targets of protective antibodies Induced by Vaccination against Smallpox. J Virol. 2016;90(9):4334.","journal-title":"J Virol"},{"issue":"2","key":"2085_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1006\/viro.1999.0096","volume":"266","author":"JW Hooper","year":"2000","unstructured":"Hooper JW, et al. DNA vaccination with Vaccinia Virus L1R and A33R genes protects mice against a Lethal Poxvirus Challenge. Virology. 2000;266(2):329\u201339.","journal-title":"Virology"},{"issue":"1","key":"2085_CR48","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1080\/22221751.2022.2095309","volume":"11","author":"Y Xiang","year":"2022","unstructured":"Xiang Y, White A. Monkeypox virus emerges from the shadow of its more infamous cousin: family biology matters. Emerg microbes infections. 2022;11(1):1768\u201377.","journal-title":"Emerg microbes infections"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-023-02085-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T06:05:37Z","timestamp":1687154737000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-023-02085-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2085"],"URL":"https:\/\/doi.org\/10.1186\/s12985-023-02085-0","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study protocol was approved by the laboratory animal management committee and the laboratory animal ethics and welfare protection group of the Shanghai Institute of Biological Products (protocol code: 2022005).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}